Compare ADMA Biologics Inc (ADMA) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Teladoc Health Inc — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Teladoc Health Inc trades at $9.14 (market cap $1.72B). The key difference: ADMA Biologics Inc is the larger of the two by market cap, and Teladoc Health Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | TDOC | |
|---|---|---|
Market Cap | $2.13B | $1.72B |
Sector | Health | Health |
52-Week High | $20.38 | $9.52 |
52-Week Low | $7.60 | $4.47 |
Enterprise Value | $2.20B | $2.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Teladoc Health (TDOC) trades at $9.52, up 3.48% today, with technical indicators showing bullish momentum despite overbought RSI readings. The company reported Q1 2026 earnings that missed expectations, but revenue remains stable at $2.53 billion for 2025. Recent news highlights expansion through Walmart's platform and ongoing cost-cutting efforts, though BetterHelp segment weakness persists. Analyst consensus is mixed with 33% buy ratings but a price target below current levels at $7.83.
TDOC's recovery story faces headwinds from persistent net losses and negative cash flow, but low P/S ratio of 0.66 offers valuation appeal. Key risks include competitive pressure and execution challenges, while institutional sentiment remains cautious with no sell ratings. The stock's near-term direction hinges on Q2 earnings results and progress toward profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
